ClinicalTrials.gg
CompletedNCT01845077Updated Aug 19, 2014Results posted

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

A Phase 1 interventional study of 2x500 mg Metformin (Glumetza) and 5 mg Linagliptin/1000 mg Metformin FDC in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-19.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of the trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combination (FDC) tablets containing linagliptin \& metformin and the single tablets of linagliptin and metformin when administered singularly.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or females
  2. Age 18 -50 years (incl)
  3. (BMI) 18.5 to 29.9 kg/m2 (incl.)
  4. Subjects must be able to understand and comply with study requirements

Exclusion criteria

Exclusion criteria:

Any deviation from healthy condition

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Active comparator
    5 mg Linagliptin/1000 mg Metformin, fed

    3 single tablets under fed conditions

    Drug: 2x500 mg Metformin (Glumetza) · Drug: 5 mg Linagliptin (Tradjenta)

  • Experimental
    5 mg Linagliptin/1500 mg Metformin FDC

    2 FDC tablets under fasted conditions

    Drug: 2 x 2.5 mg Linagliptin/750 mg Metformin FDC

  • Active comparator
    5 mg Linagliptin/1500 mg Metformin

    4 single tablets under fasted conditions

    Drug: 3x500 mg Metformin (Glumetza) · Drug: 5 mg Linagliptin (Tradjenta)

  • Experimental
    5 mg Linagliptin/1000 mg Metformin FDC

    1 fixed dose combination(FDC) tablet under fasted conditions

    Drug: 5 mg Linagliptin/1000mg Metformin FDC

  • Active comparator
    5 mg Linagliptin/1000 mg Metformin

    3 single tablets under fasted conditions

    Drug: 5 mg Linagliptin (Tradjenta) · Drug: 2 x 500 mg Metformin (Glumetza)

  • Experimental
    5mg Linagliptin/1000mg Metformin, FDCfed

    1 FDC tablet under fed conditions

    Drug: 5 mg Linagliptin/1000 mg Metformin FDC

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-72 of Linagliptin

    Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72). The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period

  2. Cmax of Linagliptin

    Maximum Measured Concentration (Cmax) of Linagliptin in plasma. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period

  3. AUC0-tz of Metformin

    Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period

  4. Cmax of Metformin

    Maximum Measured Concentration (Cmax) of Metformin in plasma. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period

Secondary outcomes

  1. AUC0-infinity of Linagliptin

    Area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 extrapolated to infinity based on predicted last concentration values. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period

  2. AUC0-infinity of Metformin

    Area under the concentration-time curve of Metformin in plasma over the time interval from 0 extrapolated to infinity based on predicted last concentration values. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period

07

Results

Posted Aug 19, 2014

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneFDC1000 Fasted, Then L+M1000 FastedL+M1000 Fasted, Then FDC1000 FastedFDC1000 Fed, Then L+M1000 FedL+M1000 Fed, Then FDC1000 FedFDC1500 Fasted, Then L+M1500 FastedL+M1500 Fasted, Then FDC1500 Fasted
Started121212121212
Completed121212121212
Not completed000000
Washout Period
Participant flow — Washout Period
MilestoneFDC1000 Fasted, Then L+M1000 FastedL+M1000 Fasted, Then FDC1000 FastedFDC1000 Fed, Then L+M1000 FedL+M1000 Fed, Then FDC1000 FedFDC1500 Fasted, Then L+M1500 FastedL+M1500 Fasted, Then FDC1500 Fasted
Started121212121212
Completed111111101111
Not completed111211
Withdrew: Lost to follow-up010101
Withdrew: Adverse event100000
Withdrew: Elevated lab values (not clinic. sign.)001000
Withdrew: Protocol violation000110
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneFDC1000 Fasted, Then L+M1000 FastedL+M1000 Fasted, Then FDC1000 FastedFDC1000 Fed, Then L+M1000 FedL+M1000 Fed, Then FDC1000 FedFDC1500 Fasted, Then L+M1500 FastedL+M1500 Fasted, Then FDC1500 Fasted
Started111111101111
Completed111111101111
Not completed000000

Outcome measures

PrimaryAUC0-72 of Linagliptin

Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72). The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period
Reported as:
Geometric mean · nmol*h/L
AUC0-72 of Linagliptin
nmol*h/LFDC1000 FastedL+M1000 FastedFDC1000 FedL+M1000 FedFDC1500 FastedL+M1500 Fasted
AUC0-72 of Linagliptin317.0 ± 8.0319.2 ± 8.0309.6 ± 5.5304.9 ± 5.5325.8 ± 5.1322.9 ± 5.1
Statistical analysis
  • FDC1000 Fasted vs L+M1000 Fasted · ANOVA · Ratio of geometric means: 99.3 · 90% CI 95.3 to 103.5ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
  • FDC1000 Fed vs L+M1000 Fed · ANOVA · Ratio of geometric means: 101.5 · 90% CI 98.4 to 104.7ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
  • FDC1500 Fasted vs L+M1500 Fasted · ANOVA · Ratio of geometric means: 100.9 · 90% CI 98.2 to 103.7ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
PrimaryCmax of Linagliptin

Maximum Measured Concentration (Cmax) of Linagliptin in plasma. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period
Reported as:
Geometric mean · nmol/L
Cmax of Linagliptin
nmol/LFDC1000 FastedL+M1000 FastedFDC1000 FedL+M1000 FedFDC1500 FastedL+M1500 Fasted
Cmax of Linagliptin10.1 ± 17.110.6 ± 17.17.7 ± 13.07.9 ± 13.011.6 ± 16.510.7 ± 16.5
Statistical analysis
  • FDC1000 Fasted vs L+M1000 Fasted · ANOVA · Ratio of geometric means: 94.9 · 90% CI 86.8 to 103.6ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
  • FDC1000 Fed vs L+M1000 Fed · ANOVA · Ratio of geometric means: 96.8 · 90% CI 90.2 to 103.8ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
  • FDC1500 Fasted vs L+M1500 Fasted · ANOVA · Ratio of geometric means: 108.6 · 90% CI 99.5 to 118.5ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
SecondaryAUC0-infinity of Linagliptin

Area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 extrapolated to infinity based on predicted last concentration values. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period
Reported as:
Geometric mean · nmol*h/L
AUC0-infinity of Linagliptin
nmol*h/LFDC1000 FastedL+M1000 FastedFDC1000 FedL+M1000 FedFDC1500 FastedL+M1500 Fasted
AUC0-infinity of Linagliptin546.1 ± 12.8526.5 ± 12.8537.1 ± 9.6510.0 ± 9.6562.9 ± 13.5581.1 ± 13.5
Statistical analysis
  • FDC1000 Fasted vs L+M1000 Fasted · ANOVA · Ratio of geometric means: 103.7 · 90% CI 97.1 to 110.8ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
  • FDC1000 Fed vs L+M1000 Fed · ANOVA · Ratio of geometric means: 105.3 · 90% CI 99.9 to 111.0ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
  • FDC1500 Fasted vs L+M1500 Fasted · ANOVA · Ratio of geometric means: 96.9 · 90% CI 90.2 to 104.1ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
SecondaryAUC0-infinity of Metformin

Area under the concentration-time curve of Metformin in plasma over the time interval from 0 extrapolated to infinity based on predicted last concentration values. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period
Reported as:
Geometric mean · ng*h/mL
AUC0-infinity of Metformin
ng*h/mLFDC1000 FastedL+M1000 FastedFDC1000 FedL+M1000 FedFDC1500 FastedL+M1500 Fasted
AUC0-infinity of Metformin9037.6 ± 21.59326.5 ± 21.514031.3 ± 7.014069.7 ± 7.011037.7 ± 19.111512.2 ± 19.1
Statistical analysis
  • FDC1000 Fasted vs L+M1000 Fasted · ANOVA · Ratio of geometric means: 96.9 · 90% CI 86.8 to 108.2ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
  • FDC1000 Fed vs L+M1000 Fed · ANOVA · Ratio of geometric means: 99.7 · 90% CI 96.1 to 103.5ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
  • FDC1500 Fasted vs L+M1500 Fasted · ANOVA · Ratio of geometric means: 95.9 · 90% CI 86.7 to 106.0ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
PrimaryAUC0-tz of Metformin

Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period
Reported as:
Geometric mean · ng*h/mL
AUC0-tz of Metformin
ng*h/mLFDC1000 FastedL+M1000 FastedFDC1000 FedL+M1000 FedFDC1500 FastedL+M1500 Fasted
AUC0-tz of Metformin8629.0 ± 21.88913.7 ± 21.813772.0 ± 7.413851.1 ± 7.410472.9 ± 18.510543.5 ± 18.5
Statistical analysis
  • FDC1000 Fasted vs L+M1000 Fasted · ANOVA · Ratio of geometric means: 96.8 · 90% CI 86.6 to 108.2ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
  • FDC1000 Fed vs L+M1000 Fed · ANOVA · Ratio of geometric means: 99.4 · 90% CI 95.6 to 103.4ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
  • FDC1500 Fasted vs L+M1500 Fasted · ANOVA · Ratio of geometric means: 99.3 · 90% CI 90.1 to 109.5ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
PrimaryCmax of Metformin

Maximum Measured Concentration (Cmax) of Metformin in plasma. The shown geometric coefficients of variation (gCV) are the pooled intra-individual gCV - each over 2 treatment groups (FDC1000 fasted and L+M1000 fasted, FDC1000 fed and L+M1000 fed, FDC1500 fasted and L+M1500 fasted). The geometric means are actually adjusted geometric means.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40 min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration at Day 1 of each treatment period
Reported as:
Geometric mean · ng/mL
Cmax of Metformin
ng/mLFDC1000 FastedL+M1000 FastedFDC1000 FedL+M1000 FedFDC1500 FastedL+M1500 Fasted
Cmax of Metformin1047.4 ± 25.51085.6 ± 25.51119.0 ± 8.11084.5 ± 8.11347.0 ± 29.31250.6 ± 29.3
Statistical analysis
  • FDC1000 Fasted vs L+M1000 Fasted · ANOVA · Ratio of geometric means: 96.5 · 90% CI 84.8 to 109.8ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
  • FDC1000 Fed vs L+M1000 Fed · ANOVA · Ratio of geometric means: 103.2 · 90% CI 98.9 to 107.7ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.
  • FDC1500 Fasted vs L+M1500 Fasted · ANOVA · Ratio of geometric means: 107.7 · 90% CI 92.5 to 125.4ANOVA on the logarithmic scale, adjusted for subjects within sequences as random effect and sequence, period and treatment as fixed effects.

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FDC1000 Fasted—0/23 (0%)1/23 (4.3%)
L+M1000 Fasted—0/23 (0%)1/23 (4.3%)
FDC1000 Fed—0/22 (0%)1/22 (4.5%)
L+M1000 Fed—1/23 (4.3%)0/23 (0%)
FDC1500 Fasted—0/23 (0%)3/23 (13%)
L+M1500 Fasted—0/23 (0%)2/23 (8.7%)
Most frequent serious events
Most frequent serious events
EventFDC1000 FastedL+M1000 FastedFDC1000 FedL+M1000 FedFDC1500 FastedL+M1500 Fasted
Road traffic accidentInjury, poisoning and procedural complications0/230/230/221/230/230/23
Most frequent other events
Most frequent other events
EventFDC1000 FastedL+M1000 FastedFDC1000 FedL+M1000 FedFDC1500 FastedL+M1500 Fasted
HeadacheNervous system disorders1/231/231/220/230/232/23
NauseaGastrointestinal disorders0/230/230/220/232/231/23
VomitingGastrointestinal disorders0/230/230/220/232/231/23

Baseline characteristics

Treated set (TS) including all subjects who had been dispensed study medication and were documented to have taken at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Total 1000 FastedTotal 1000 FedTotal 1500 FastedTotal
Mean34.8 ± 9.330.6 ± 9.028.4 ± 7.131.3 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Total 1000 FastedTotal 1000 FedTotal 1500 FastedTotal
Female881430
Male16161042
08

Study locations

1 site
  • 1288.8.1 Boehringer Ingelheim Investigational Site
    Austin, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2013
First posted
May 3, 2013
Start
May 2013
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Aug 19, 2014
Last update
Aug 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01845077
Responsible party
Sponsor
First posted
May 3, 2013
Start date
May 2013
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Aug 19, 2014
Last update
Aug 19, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linagliptin · Metformin

Start the discussion